Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen to Participate in Two Upcoming Investor Conferences
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount? [Yahoo! Finance]
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy